[Nosocomial gastrointestinal infections and Clostridioides difficile]

Area of Science:

• Infectious Diseases
• Microbiology
• Gastroenterology

Background:

• Nosocomial infections affect 5.2% of hospitalized patients in Germany.
• Clostridioides difficile infections (CDI) are the leading cause of hospital-acquired diarrhea.
• CDI results from antibiotic use altering gut microbiota, with varied clinical presentations.

Purpose of the Study:

• To summarize current treatment guidelines for Clostridioides difficile infections (CDI).
• To highlight preferred and alternative therapeutic options for CDI management.
• To address CDI recurrence and advanced treatment strategies.

Main Methods:

• Review of German Gastrointestinal Infection Guidelines.
• Analysis of treatment recommendations for CDI.
• Inclusion of data on recurrence and alternative therapies.

Main Results:

• Fidaxomicin is the preferred CDI treatment, especially for high-risk or recurrent cases.
• Vancomycin serves as an alternative for initial CDI treatment.
• Fecal microbiota transplantation is an option for multiple CDI recurrences.

Conclusions:

• Current guidelines recommend specific agents for CDI treatment based on recurrence risk.
• Treatment strategies for CDI range from antibiotics to fecal microbiota transplantation.
• Effective management of CDI is crucial for reducing hospital-acquired infections and improving patient outcomes.